Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.

Cross, N.C.P., White, H.E., Colomer, D., Ehrencrona, H., Foroni, L., Gottardi, E., et al. (2015). Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. LEUKEMIA, 29(5), 999-1003 [10.1038/leu.2015.29].

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

MARTINELLI, GIOVANNI;
2015

Abstract

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
2015
Cross, N.C.P., White, H.E., Colomer, D., Ehrencrona, H., Foroni, L., Gottardi, E., et al. (2015). Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. LEUKEMIA, 29(5), 999-1003 [10.1038/leu.2015.29].
Cross, N C P; White, H E; Colomer, D; Ehrencrona, H; Foroni, L; Gottardi, E; Lange, T; Lion, T; Machova Polakova, K; Dulucq, S; Martinelli, G; Opplige...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/548720
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 102
  • Scopus 272
  • ???jsp.display-item.citation.isi??? 244
social impact